Axl-IN-21 is a selective and potent inhibitor of wild-type Axl with IC50 of 2.2 nM.

AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β.

Avobenzone(Parsol 1789)

AVG-233 (AVG233) is a potent, allosteric inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp) complex, demonstrates nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates (EC50=34-79 nM).

AVE-0118 is a potent I(to)/I(Kur) blocker, Kv1.5 channel inhibitor with IC50 of 5.6 uM, also blocks Kv1.3, Kv2.1, Kv3.1, and Kv4.3 channels with similar potency.

Avanbulin (BAL27862, BAL-27862) is a novel microtubule-destabilizing agent that potently inhibits tubulin assembly at 37°C with IC50 of 1.4 uM in tubulin-binding assays.

Auxin agonist RN4 (RubNeddin 4) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.

Auxin agonist RN3 (RubNeddin 3) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.

Autotaxin inhibitor compound 1 (Autotaxin-IN-1) is a potent, selective, orally bioavailable inhibitor of autotaxin with IC50 of 2.2 nM in ex vivo human whole blood assay, does not inhibit related proteins ENPP1 and ENPP7.

Autotaxin inhibitor 12 is a highly potent, selective, orally-bioavailable inhibitor of autotaxin with IC50 of 3.1 nM in choline release assays.

Aurintricarboxylic acid (ATA) is a potent small molecule inhibitor of RISC loading with IC50 of 0.47 uM, inhibits RISC activity against transiently expressed reporters and endogenous genes.

Aurantiamide acetate suppresses the growth of malignant gliomas in vitro and in vivo by inhibiting autophagic flux.

AU1 (GSK 1379725A) is the first selective small molecule inhibitor of BPTF bromodomain (bromodomain PHD finger transcription factor) with Kd of 2.8 uM in a cell-based reporter assay, shows no binding activity for Brd4.

ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS.

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

ATP (Adenosine-Triphosphate)

Atomoxetine ((R)-Tomoxetine.

Atocalcitol

ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia..

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro.

AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45.

AT-090 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM.

ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 hydrochloride is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.